During the Covid-19 pandemic, patient-first approaches including telemedicine and virtual care options are essential to address the unique medical coordination needs of patients with rare lung diseases, including Alpha-1 antitrypsin deficiency (Alpha-1). This genetic disease can cause severe lung disease in adults and/or liver disease at any age.
Many of these patients face the challenge of obtaining much-needed treatment compliance support, while also coping with increased stress caused by immunosuppression, increased awareness of infection, and hypersensitivity to the virus threat. The patient-first approach provides a proactive, process-driven program that uses telemedicine consultation to effectively reduce the spread of infections (such as coronavirus) in these vulnerable groups.
This strategy ensures the continuity of care throughout the patient journey through strong communication to generate rich data that clinicians can use to make more informed decisions and improve the overall patient experience. This focus also addresses the variables surrounding data collection while maintaining frequent communication with patients and their families to ensure compliance and positive results.
Understanding Alpha-1
Alpha-1 is a Genetic condition This is often referred to as “hereditary COPD”. It affects approximately 100,000 people in the United States. This disease is usually first diagnosed as asthma or smoking-related chronic obstructive pulmonary disease (COPD). COPD includes emphysema and chronic bronchitis. Alpha-1 may not be detected in approximately 3% of all people diagnosed with COPD.
The threat of Covid-19 is obvious to this community because it can cause pulmonary complications such as pneumonia And, in the worst case, Acute respiratory distress syndrome. septicemiaIt is another possible complication of Covid-19, which can also cause lasting damage to the lungs and other organs.
People with Alpha-1 are likely to be Particularly vulnerable The impact of Covid-19 infection and is considered to be one of the most vulnerable to serious complications.
Symptoms that can distinguish the deterioration of typical lung disease from Covid-19 include fever that lasts for several days or high fever of any duration, loss of smell or taste, fatigue, muscle aches, diarrhea, abdominal pain, and decreased oxygen levels.
Although the technical solutions that usually accompany the standard methods of professional pharmacies (SP) are valuable, they often fail to meet human needs and variability. This is where the patient-first model and dedicated care team are strongly recommended, providing the opportunity to go beyond any limitations of the SP and provide a comprehensive patient experience.
Advanced support for Alpha-1 patients
The patient-first care team includes care coordinators, pharmacists, nurses, and other experts who focus on disease, patient community, and treatment. SPs and patient management organizations that emphasize a patient-first approach are partners in personalized care.
The most ideal specialist and patient management partner provide a comprehensive set of services designed to maximize treatment opportunities for Alpha-1 and other rare and orphan diseases. These professionals provide a trustworthy way for patients and all those involved in treatment. This adds much-needed support to patients’ families and caregivers, enabling them to participate more actively and have ownership, thereby building stronger partnerships and better patient care.
Telemedicine
The partner’s telemedicine solution should aim to simplify patient registration, maximize interaction with patients to ensure compliance and compliance, and provide continuous care to avoid treatment errors. It should rely on dedicated team members who have expertise in all aspects of patient medication and can solve every problem and concern of patients, pharmacists, doctors, providers, and payers.
Effective telemedicine is especially important to address the unique medical coordination needs of patients with rare or orphan diseases, and more importantly, newly diagnosed patients.
As part of a larger personalized care plan and specifically associated with specific specialty medicines, telemedicine enables pharmacists to enable their patients to thrive even during the Covid-19 pandemic and other unforeseen emergencies The same is true for periods of destruction and uncertainty.
Customized care coordination and telemedicine solutions add a layer to proactive, process-driven planning to educate patients and their caregivers about potential risks. This facilitates discussions between patients and providers, which is essential for understanding the needs of patients, providing attention to the effects of medications and monitoring overall health. By combining monthly assessments and pre-determined touch points, the care team can grasp side effects and obtain real-world evidence around treatment, disease, and people’s health.
Meet the needs of stakeholders
The most effective professional partners provide expertise to navigate the insurance landscape and pre-authorization process as needed, and know how to monitor and encourage compliance. It is also important to find a partner who is dual-certified by the Utilization Review and Accreditation Council (URAC) to comply with the Professional Pharmacy and Healthcare Accreditation Council (ACHC) Professional Pharmacy Service Compliance. This shows that we are committed to providing quality care and services to these patient groups.
Ultimately, care management solutions should meet the needs of everyone involved in the journey of patients with rare diseases, from specialized drug manufacturers to pharmacists, caregivers and doctors.
Photo: The Cyclone Project, Getty Images
